BioRestorative Therapies BRTX, a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a notice of allowance for a patent application related to its metabolic ThermoStem® program. The Notice of Allowance signals the end of the examination process for the patent application. It indicates that the European Patent Office has determined that the ThermoStem® program is novel, non-obvious, and fully and particularly described in the patent application.
The Notice of Allowance is a testament to BioRestorative’s commitment to innovation and advancing medical science through developing novel therapies utilizing adult stem cells. With this milestone, BioRestorative has made significant strides toward achieving its mission of developing and commercializing cell-based products and therapeutics for various metabolic conditions – such as diabetes and obesity – across key international markets. This patent will provide the company with protection for its proprietary ThermoStem® process, which is being developed for the treatment of metabolic syndrome.
Metabolic syndrome is a cluster of conditions, such as obesity and increased cholesterol (fat) and glucose in the blood, that increase the risk of type 2 diabetes, heart disease and stroke. The ThermoStem® program harnesses the body’s ability to create new brown fat tissue from human brown adipose-derived stem cells. Pioneering research conducted by Biorestorative Therapies demonstrated that brown tissue burns rather than stores energy. Increased levels of brown tissue support weight loss by increasing metabolism and reducing sugar and fats in the blood. Thus, higher brown fat levels may address metabolic syndrome’s significant effects.
Obesity management is the subject of intense clinical development with Eli Lilly Co LLY and Pfizer Inc PFE looking to emulate the success of Semaglutide, marketed by Novo Nordisk A/S NVO for the treatment of obesity and type 2 diabetes.
“Our patent family for our ThermoStem® program continues to grow as we receive additional patent grants in key markets,” said Lance Alstodt, CEO of BioRestorative Therapies, commenting on the development. “We are committed to the development of ThermoStem® as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes. This patent, which covers a manufacturing process for ThermoStem® developed by BioRestorative’s scientists, enhances our ability to do so in European jurisdictions.”
In addition to its metabolic program (ThermoStem®), BioRestorative Therapies is pioneering the use of a patient’s bone marrow cells to treat chronic lower back pain caused by degenerative disc disease. BRTX-100 is currently being evaluated as a non-invasive alternative to surgery in patients with degenerative chronic lower back pain, with results from the clinical study expected in March or April 2023.
Visit for more information on the company and its product candidates.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Featured photo by Victoria_Watercolor on Pixabay
